Paris Saint- Germain Legend Visits Rwanda – RNA NEWS rnanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rnanews.com Daily Mail and Mail on Sunday newspapers.
Reuters
1 minute read
BRASILIA, July 7 (Reuters) - Brazilian health regulator Anvisa on Wednesday gave the go-ahead for the Butanvac COVID-19 vaccine developed by Sao Paulo s Butantan Institute biomedical center to be used on volunteers in clinical trials.
Anvisa in a statement said the vaccine will be applied in two doses, 28 days apart. Phase I of Butanvac s clinical trial will involve 400 volunteers, and the first two phases are expected to involve 6,000 volunteers in total.
In a separate statement, Butantan said the tests will begin in the coming days in Riberao Preto, a city in the state of Sao Paulo.
Butantan said it has around 10 million doses of the Butanvac shot in stock, which will be used to assess the vaccine s safety and efficacy in the trials. It hopes to have 40 million shots ready for use by October, it added.
Brazil authorizes Butanvac vaccine for volunteers in cl dailymaverick.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymaverick.co.za Daily Mail and Mail on Sunday newspapers.